Avalon GloboCare Corp. - Common Stock (ALBT)
3.2800
-0.0200 (-0.61%)
Avalon GloboCare Corp. is a healthcare innovation company focused on advanced cell-based technologies and the development of transformative treatment solutions
The firm specializes in the research, design, and commercialization of cell therapies, with a particular emphasis on addressing unmet medical needs in areas such as cancer, immunology, and regenerative medicine. By leveraging its proprietary platforms and strategic partnerships, Avalon aims to drive the next generation of cellular medicine, improving patient outcomes and enhancing the efficacy of therapies. Through its integrated approach, the company is committed to advancing the frontiers of healthcare and making a meaningful impact on global health challenges.
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Trump Media & Technology Group (NASDAQDJT), the company behind Truth Social, witnessed a sharp surge on Election Day, with shares climbing as traders bet that a second Trump presidency could reignite business prospects. The stock, often regarded as a proxy for the former president’s White House chances, has seen heavy retail interest, especially on platforms like WallStreetBets , where it topped discussions, opening the way to small cap stocks some mentioned herein.
Via AB Newswire · November 5, 2024
Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose An Attractive Value Proposition ($ALBT)
Despite weak markets, Avalon GloboCare (NASDAQALBT) stock has been able to defend its valuation. Except for a late-day blip on Tuesday, ALBT shares have been consolidating at the $3.40 level, which from current prices and ALBT having enough accretive ammo to reclaim consolidation levels, puts an 11% gain in investors' crosshairs.
Via AB Newswire · February 2, 2023
With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Breakout 2023 ($ALBT)
Avalon GloboCare (NASDAQALBT), a NASDAQ-listed company with only 3.22 million shares in the float, is better positioned than at any time in its history to accelerate growth in 2023. In fact, after completing a share consolidation, raising capital at a premium to the market, and bolstering its IP portfolio with what's being considered a breakthrough patent award, any weakness in ALBT stock may be adding to an already compelling value investment opportunity.
Via AB Newswire · January 31, 2023
Avalon GloboCare Strengthens IP Portfolio, Earns Breakthrough Patent For QTY-Code Technology ($ALBT)
Markets are dynamic. And with just a slight imbalance between buyers and sellers, more times than not, an opportunity gets exposed. That's especially true when it comes to investing, where trading imbalances of low-float companies can have an outsized effect on which way momentum trends. Take the case of Avalon GloboCare (NASDAQALBT), a NASDAQ-listed company with only 3.22 million shares in the float that is better positioned than at any time in history to accelerate growth in 2023. Its reward- a more than 36% decline in share price since the start of the year, settling Monday at $3.24.
Via AB Newswire · January 24, 2023
Avalon GloboCare Scores Patent For Breakthrough QTY-Code Technology To Expedite Developing Better Cancer Treatments ($ALBT)
Markets are dynamic. And with just a slight imbalance between buyers and sellers, more times than not, an opportunity gets exposed. That's especially true when it comes to investing, where trading imbalances of low-float companies can have an outsized effect on which way momentum trends. Take the case of Avalon GloboCare (NASDAQALBT), a NASDAQ-listed company with only 3.22 million shares in the float that is better positioned than at any time in history to accelerate growth in 2023. Its reward- a more than 35% decline in share price since the start of the year, trading Monday at $3.34.
Via AB Newswire · January 23, 2023
Avalon GloboCare Stock Completes $4.0 Million Private Placement Priced At A Premium To Accelerate Closing Accretive Acquisition ($ALBT)
Shares of Avalon GloboCare (NASDAQALBT) have been trending higher. Since December 12th, ALBT stock is over 40% higher, with shares trading today at roughly $0.45 on Friday. News from Avalon last Wednesday provided a solid reason for the bullish sentiment, showing that ALBT's intention of becoming a more prominent company is happening faster than many expected. And the better news from an investor's perspective, a fresh capital infusion can expedite that mission. (* percentage change calculated from period 12/12/22 – 12/16/22, 11:10am EST, Yahoo! Finance $0.32 - $0.45)
Via AB Newswire · December 19, 2022
Avalon GloboCare Stock Rallies On Acquisition, Partnership, And Clinical Program Updates ($ALBT)
Avalon GloboCare (NASDAQALBT) stock continues to attract investor attention. Since Monday, ALBT shares are more than 43% higher, fueled by several updates highlighting its clinical ambitions, planned accretive acquisition, and the restructuring of its management and board to better reflect Avalon's new focus on laboratory services and biotherapeutics in the United States. Besides holding a small office in Shanghai, China, all other business operations in the People's Republic of China have ceased. (* share price open on 12/12/22 – 12/15/22, $0.32 - $0.48, 9:48am EST, Yahoo! Finance)
Via AB Newswire · December 15, 2022
Avalon GloboCare Shares Higher; Partnerships And Planned Acquisition Fuel Investor Interest ($ALBT)
Thinly traded Avalon GloboCare (NASDAQALBT) stock is worthy of consideration, and savvy investors appear to be doing just that. In fact, shares moved more than 5% higher last week, touching $0.38 on higher-than-normal volume. By the way, calling ALBT shares "thinly traded" doesn't imply that they are entirely under the radar. They certainly aren't, as the average three-month volume before risk-off markets shows shares exchanging hands at over 200,000 per day. So, while ALBT isn't a biotech investment secret in many respects, its value proposition may present a timely opportunity while investors are still looking elsewhere to park their money.
Via AB Newswire · December 13, 2022